Lentiviral-mediated Gene Therapy for Pediatric Patients With Fanconi Anemia Subtype A
Study sponsor: Rocket Pharmaceuticals Inc. · RCKT
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2025-02Estimated
Enrollment · participants7Actual
Source updated2024-05-22Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.